Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9300417 | 0.98 | KCNH2 (0.46) | NOS1KCNH2HTR2AHTR2CTLR8 | |
| SCHEMBL9299469 | 0.95 | NOS1 (0.47) | NOS1HTR2AHTR2CTLR8PLK4 | |
| SCHEMBL24249558 | 0.88 | NOS1 (0.50) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL30402313 | 0.82 | NOS1 (0.47) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL24210702 | 0.82 | NOS1 (0.51) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL30400230 | 0.82 | NOS1 (0.51) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL18188519 | 0.82 | NOS1 (0.47) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL12181032 | 0.81 | NOS1 (0.53) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL24210802 | 0.78 | NOS1 (0.50) | NOS1HTR2AHTR2CPLK4CHEK1 | |
| SCHEMBL24210664 | 0.78 | NOS1 (0.55) | NOS1HTR2AHTR2CPLK4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911364-B2 | Positive allosteric modulators of GABAA receptor | PEPTICOM LTD. (IL) | 2024-02-27 | — | — | US | disclosed |
| US-20210353592-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | PEPTICOM LTD. (IL) | 2021-11-18 | — | — | US | disclosed |
| US-20200283502-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | PEPTICOM LTD. (IL) | 2020-09-10 | — | — | US | disclosed |
| WO-2020065642-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | PEPTICOM LTD. (IL) | 2020-04-02 | — | — | WO | disclosed |
| WO-2019058349-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | PEPTICOM LTD (IL) | 2019-03-28 | — | — | WO | disclosed |
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2007753-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. Hoffmann-Roche AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007115966-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | NOS1 3471/4885KCNH2 461/4885HTR2A 157/4885 |
| US-20210353592-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTOR | GABRP, GABRB2, GABRB1 | NOS1 2760/4885KCNH2 990/4885HTR2A 149/4885 |
| US-11911364-B2 | Positive allosteric modulators of GABAA receptor | GABRP, GABRB2, GABRB1 | NOS1 2760/4885KCNH2 990/4885HTR2A 149/4885 |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | NOS1 3717/4885KCNH2 553/4885HTR2A 60/4885 |
| US-20200283502-A1 | POSITIVE ALLOSTERIC MODULATORS OF GABA A RECEPTOR | GABRB3, GABRB1, GABRB2 | NOS1 224/4885KCNH2 850/4885HTR2A 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.